Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/TherapeuticsMD, Inc./ 10-K

Annual Report · 10-K

TherapeuticsMD, Inc.

TXMDNASDAQEQUITYCurrent

Annual Report

Filed Mar 30, 2026Accepted Mar 30, 2026, 5:43 PM EDTCIK 25743Accession 0001213900-26-036515
View company →Permanent SEC source ↗
Share

Company context

TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, the Company changed its business to become a pharmaceutical royalty company, primarily collecting royalties from its licensees. The Company is no longer engaging in research and development or commercial operations.

Current securities

TXMDNASDAQ · EQUITY · Current

Recent company filings

  1. 10-Q filingAug 11, 2026
  2. Results of Operations and Financial Condition · Regulation FD DisclosureAug 11, 2026
  3. SCHEDULE 13G/A - filed by Baselake Partners, LP regarding TherapeuticsMD, Inc.Aug 5, 2026
  4. 10-Q filingMay 12, 2026
  5. Results of Operations and Financial Condition · Regulation FD DisclosureMay 12, 2026

Registered securities in this filing

THERAPEUTICSMD, INC. · 10-K · Filed 2026-03-30

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.001 per share

Symbol
TXMD
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: c0

Dimensions: Not supplied

Accession 000121390026036515 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.